21 suspended. 21 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Suspended 21 |
| Phase 2 | 7 | Suspended 7 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-11-30 | 2026-10-30 |
| Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Suspended | Petrov, Andrey | 10 | 2026-05-20 | 2026-06-03 |
| Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization Autologous total tumor mRNA loaded DOTAP liposome vaccine - Melanoma, Soft Tissue Sarcoma | Phase 1 | Suspended | University of Florida | 18 | 2026-03-17 | 2026-09-17 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| IL13Rα2 CAR-T for Patients With r/r Glioma IL13Rα2 CAR-T - Glioma | Phase 1 | Suspended | Yang Zhang | 30 | 2024-03-21 | 2026-10-01 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 73 | 2022-01-25 | 2026-11-18 |
| DNX-2440 for Resectable Colorectal Liver Metastasis DNX-2440 - Liver Metastases, Liver Metastasis Colon Cancer | Phase 1 | Suspended | DNAtrix, Inc. | 30 | 2021-02-15 | 2024-04-09 |
| Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma 18F-FMISO PET, 18F-FLT PET - Glioma | Phase 1 | Suspended | Weill Medical College of Cornell University | 8 | 2021-02-01 | 2026-01-27 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations JSI-1187, Dabrafenib - Solid Tumors | Phase 1 | Suspended | JS InnoPharm, LLC | 71 | 2020-06-18 | 2025-09-03 |
| Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) Laparoscopically harvested omental free flap - Glioma, Glioma, Malignant | Phase 1 | Suspended | Northwell Health | 10 | 2020-01-06 | 2026-06-01 |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2 - Solid Tumor | Phase 1 | Suspended | PACT Pharma, Inc. | 21 | 2019-07-03 | 2022-08-18 |
| MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) FCN-159 - Melanoma | Phase 1 | Suspended | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 79 | 2019-03-21 | 2024-03-27 |
| Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 1 / Phase 2 | Suspended | Roswell Park Cancer Institute | 47 | 2018-01-31 | 2026-07-15 |
| Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation P1446A-05, Vemurafenib (Zelboraf®) - Advanced or Inoperable Malignant Melanoma With BRAF Mutation | Phase 1 | Suspended | Piramal Enterprises Limited | 100 | 2013-08-01 | 2014-09-04 |
| Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma TPI 287, Bevacizumab - Glioblastoma Multiforme | Phase 1 / Phase 2 | Suspended | Cortice Biosciences, Inc. | 92 | 2013-08-01 | 2023-02-22 |
| Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Bevacizumab and Carboplatin - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Suspended | Northwell Health | 54 | 2011-09-01 | 2026-06-01 |
| Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Bevacizumab (Avastin) - Vestibular Schwannoma | Phase 1 | Suspended | Northwell Health | 30 | 2011-08-01 | 2026-06-01 |
| Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer Autologous Natural Killer / Natural Killer T Cell Immunotherapy - Breast Cancer, Glioma | Phase 1 | Suspended | Envita Medical Center, Inc. | 24 | 2009-05-01 | 2010-02-24 |
| Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients Melan-A analog peptide - Melanoma | Phase 1 | Suspended | University of Lausanne Hospitals | 6 | 2004-07-01 | 2005-09-12 |
Showing 20 of 21. Sign in to see all of them.
Melanoma (10) · Glioblastoma (5) · Glioma (5) · Brain Neoplasms (4) · Neoplasms (4) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Astrocytoma (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1)
Neoplasms by Histologic Type (21) · Neoplasms, Germ Cell and Embryonal (21) · Neoplasms, Nerve Tissue (20) · Neoplasms (17) · Neoplasms by Site (15) · Neoplasms, Glandular and Epithelial (14) · Neuroendocrine Tumors (11) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Neoplasms, Neuroepithelial (10) · Nevi and Melanomas (10) · Skin Neoplasms (10) · Brain Diseases (5) · Central Nervous System Diseases (5)
Bevacizumab (4) · Biopsy (2) · Nivolumab (2) · Specimen Handling (2) · pembrolizumab (2) · CA-4948 (1) · Carboplatin (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · Interleukin-2 (1) · Magnetic Resonance Spectroscopy (1) · Nanoparticles (1) · Propranolol (1) · Radiosurgery (1) · TPI-287 (1)
Northwell Health (3) · Cortice Biosciences, Inc. (1) · DNAtrix, Inc. (1) · Envita Medical Center, Inc. (1) · JS InnoPharm, LLC (1) · Mayo Clinic (1) · MetaPhore Pharmaceuticals (1) · National Cancer Institute (NCI) (1) · NaviFUS Corporation (1) · PACT Pharma, Inc. (1) · Petrov, Andrey (1) · Piramal Enterprises Limited (1) · Roswell Park Cancer Institute (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · University of Florida (1)
United States (17) · China (2) · Georgia (1) · Kazakhstan (1) · Switzerland (1) · Ukraine (1)
John Boockvar, MD (3) · Adil Daud, MD (1) · Bently Doonan, MD, MS (1) · David Korn, D.O., M.D. (1) · Eric M Thompson, M.D. (1) · J. P. Duic, M.D. (1) · Jian Campian, M.D. (1) · Joan Robbins, Ph.d (1) · Kevin B Kim, MD (1) · Leighton Elliott, MD (1) · Louis B. Nabors, III, M.D. (1) · Nan Ji, MD, PhD (1) · Nimish Mohile, M.D. (1) · Pierre Giglio, M.D. (1) · Rosandra N Kaplan (1)
PMID 35537408, PMID 36113242, PMID 36356599
R01CA296813 (1), U24CA224309 (1), UM1CA154967 (1), UM1CA228823 (1)